Evidence map›Paper›PMID 41754532›Full record

ArticleViruses2026

Molecular Characterization of Persistent SARS-CoV-2 Infections in Immunocompromised Patients.

Patricia Volkow-Fernández, Marco Villanueva-Reza, Santiago Ávila-Ríos, Enrique Mendoza-Ramírez, América Citlali Vera-Jimenez, Alexandra Martin-Onraet, Beda Islas-Muñoz, Pamela Alatorre-Fernández, Rogelio Pérez-Padilla, Daniel Carpio-Guadarrama and 6 more

Abstract readCase Reports
In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Patricia Volkow-FernándezDepartment of Infectious Diseases, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.ORCID 0000-0002-1991-0923
Marco Villanueva-RezaHospital Epidemiology and Infectology Department, Instituto Nacional Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City 14080, Mexico.ORCID 0000-0001-5690-2941
Santiago Ávila-RíosCentro de Investigación en Enfermedades Infecciosas, Instituto Nacional Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City 14080, Mexico.
Enrique Mendoza-RamírezLaboratory of Molecular Biology of Emergent Infectious Disease, Instituto Nacional Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City 14080, Mexico.ORCID 0009-0009-4900-5965
América Citlali Vera-JimenezLaboratory of Molecular Biology of Emergent Infectious Disease, Instituto Nacional Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City 14080, Mexico.
Alexandra Martin-OnraetDepartment of Infectious Diseases, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.ORCID 0000-0002-8627-404X
Beda Islas-MuñozDepartment of Infectious Diseases, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.ORCID 0000-0002-8720-617X
Pamela Alatorre-FernándezDepartment of Infectious Diseases, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.ORCID 0000-0002-8873-8573
Rogelio Pérez-PadillaDepartment of Research in Tobacco and COPD, Instituto Nacional Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City 14080, Mexico.
Daniel Carpio-GuadarramaDepartment of Infectious Diseases, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.ORCID 0009-0005-7252-7666
Andrea Cárdenas-OrtegaCentro de Investigación en Enfermedades Infecciosas, Instituto Nacional Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City 14080, Mexico.ORCID 0009-0000-1827-3283
Víctor Hugo Ahumada-TopeteHospital Epidemiology and Infectology Department, Instituto Nacional Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City 14080, Mexico.
Clara EspitiaDepartment of Immunology, Institute of Biomedical Research, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, Mexico.
Karen Lizbeth Reyes-BarreraDepartment of Immunology, Institute of Biomedical Research, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, Mexico.ORCID 0000-0003-3251-4236
Edgar Sevilla-ReyesLaboratory of Transcriptomics and Molecular Immunology, Instituto Nacional Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City 14080, Mexico.ORCID 0000-0002-7047-0222
Joel Armando Vázquez-PérezLaboratory of Molecular Biology of Emergent Infectious Disease, Instituto Nacional Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City 14080, Mexico.ORCID 0000-0002-8508-3698

Funding

Direccion General de Politicas de Investigacion en Salud (DGPIS) FPIS2024-INER-4886
6 · The paper itself

Abstract

Immunocompromised patients, including those with advanced HIV infection, hematologic malignancies treated with anti-CD20 monoclonal antibodies, or combined immunodeficiencies, are at increased risk of persistent SARS-CoV-2 infection. While long-term viral shedding has been described in these patients, the extent and nature of intra-host viral evolution during long-term infection remain insufficiently documented. In this study, we report longitudinal genomic analyses of SARS-CoV-2 from three immunocompromised individuals with persistent COVID-19: (i) a female patient with follicular lymphoma receiving bendamustine-rituximab therapy with 9 months of persistence, (ii) a male patient with advanced HIV infection following prolonged antiretroviral therapy interruption with 10 months of persistence, and (iii) a female patient with Good's Syndrome characterized by combined humoral and cellular immune deficiency with apparently four years of persistence. Replication-competent virus was detected over extended periods. Sequential whole-genome sequencing revealed the gradual accumulation of non-synonymous mutations across multiple viral genes, consistent with ongoing viral replication and intra-host diversification in the absence of effective immune control. Although based on a limited number of cases, these findings provide descriptive evidence that persistent SARS-CoV-2 infection in immunocompromised hosts can be associated with sustained viral evolution. This work highlights the importance of continued virological monitoring in selected patients with prolonged infection and contributes to the understanding of SARS-CoV-2 dynamics in settings of impaired immunity.

Indexed as

COVID-19Immunocompromised HostPersistent InfectionSARS-CoV-2FemaleGenome, ViralHIV InfectionsHumansMaleMutationVirus ReplicationWhole Genome Sequencingimmunosuppressionpersistent infectionSARS-CoV-2

Identifiers

PMID41754532
PMCPMC12944910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.